BeyondSpring Enrolls First U.S. Patient in Phase 2/3 Clinical Trial of Plinabulin for Neutropenia Prevention
April 25, 2017 08:30 ET | BeyondSpring, Inc.
NEW YORK, April 25, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today...
Taconic_Logo_Vert_Process_Medium resize.jpg
Taconic Biosciences Launches ExpressMODEL™, a New Accelerated Model Generation Service
April 03, 2017 10:30 ET | Taconic Biosciences
HUDSON, N.Y., April 03, 2017 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in genetically engineered mouse models and associated services, has launched ExpressMODEL™, an innovative and...
BeyondSpring Chief Medical Officer to Present on Lead Asset Plinabulin for Chemotherapy-Induced Neutropenia Prevention at BIO-Europe Spring 2017
March 22, 2017 08:30 ET | BeyondSpring, Inc.
NEW YORK, March 22, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today...
BeyondSpring Lead Asset Plinabulin's Anti-Cancer Mechanism Accepted for Poster Presentation at the 2017 Keystone Symposia in British Columbia
March 20, 2017 08:30 ET | BeyondSpring, Inc.
NEW YORK, March 20, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today...
BeyondSpring Chief Medical Officer to Present Clinical Data for Lead Asset Plinabulin for Non-Small Cell Lung Cancer Treatment and Neutropenia Prevention at 2017 BIO Asia International Conference in Tokyo
March 14, 2017 08:30 ET | BeyondSpring, Inc.
NEW YORK, March 14, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today...
Cascadian Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results
March 09, 2017 16:01 ET | Cascadian Therapeutics, Inc.
SEATTLE, March 09, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC) today reported financial results for the fourth quarter and full year ended December 31, 2016.“In 2016, we...
Cascadian Therapeutics Announces 2017 Outlook and Recent Drug Portfolio Progress
January 05, 2017 08:00 ET | Cascadian Therapeutics, Inc.
SEATTLE, Jan. 05, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced an overview of recent progress for its...
IGC Announces Financial Results for Fiscal Year Ended March 31, 2016
July 18, 2016 08:30 ET | India Globalization Capital
BETHESDA, Md., July 18, 2016 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE MKT:IGC) announces financial results for the fiscal year ended March 31, 2016.  Total revenue was...
IGC Expands Phytocannabinoid IP Portfolio with Patent Filing for Method & Composition for Treating Seizure Disorders
June 20, 2016 08:00 ET | India Globalization Capital
BETHESDA, Md., June 20, 2016 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE:IGC) announces today that it has filed a patent related to compositions and methods for treating multiple...
IGC Files International Applications for Cannabinoid Composition and Method Patents
March 15, 2016 08:30 ET | India Globalization Capital
Bethesda, Md, March 15, 2016 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (IGC) announces today that it has expanded the scope of its patent strategy to include international patent...